In the past decade RNA-based therapies such as small interfering RNA (siRNA) and
messenger RNA (mRNA) have emerged as new and ground-breaking therapeutic agents for …

RNA-based medicine is receiving growing attention for its diverse roles and potential
therapeutic capacity. The largest obstacle in its clinical translation remains identifying a safe …

In recent years, RNA-based therapies have gained much attention as biomedicines due to
their remarkable therapeutic effects with high specificity and potency. Lung diseases offer a …

With recent advances in the field of RNAi-based therapeutics, it is possible to make any
target gene 'druggable', at least in principle. The present review focuses on aspects critical …

Inhaled delivery of mRNA has the potential to treat a wide variety of diseases. However,
nebulized mRNA lipid nanoparticles (LNPs) face several unique challenges including …

RNA interference (RNAi) is a potent and specific post-transcriptional gene silencing process.
Since its discovery, tremendous efforts have been made to translate RNAi technology into …

Obstructive airway diseases, eg, chronic obstructive pulmonary disease (COPD) and
asthma, represent leading causes of morbidity and mortality worldwide. However, the …

The emergence of RNAi offers a potentially exciting new therapeutic paradigm for
respiratory diseases. However, effective delivery remains a key requirement for their …

Lung diseases are the leading cause of mortality worldwide. The currently available
therapies are not sufficient, leading to the urgent need for new therapies with sustained anti …

Messenger RNA is a class of promising nucleic acid therapeutics to treat a variety of
diseases, including genetic diseases. The development of a stable and efficacious mRNA …